Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Rivaroxaban (Primary) ; Phenprocoumon
- Indications Atrial fibrillation; Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms IRIVASC
- 22 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2019.
- 22 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 12 May 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2019.